Activated hepatic stellate cells (HSCs) play a key role in liver fibrosis and inactivating HSCs has been considered a promising therapeutic approach. We previously showed that albumin and its derivative, retinol binding protein (RBP)-albumin domain III fusion protein (named R-III), inhibit HSC activation. Here, we investigate the mode of action of albumin and R-III.
Introduction
Stellate cells, commonly known as hepatic stellate cells (HSCs), are first mentioned by Von Kupffer in 1876 [1] . HSCs are pericytes found in the perisinusoidal space of the liver and constitute approximately 5-8% of total liver cells [2] . They are in a quiescent state with nonproliferative characteristic in the normal liver and represent the major storage site for retinoids. About 80 % of the total body vitamin A (retinol) is stored as retinyl esters in lipid droplets in the cytoplasm. Upon response to fibrogenic stimuli, quiescent stellate cells undergo functional and phenotypical changes, referred to as "activation", and transform into myofibroblast-like cells [3] . This process is characterized by loss of cytoplasmic vitamin Acontaining lipid droplets, high cellular proliferation, positive staining for α-smooth muscle actin (α-SMA), and greatly increased synthesis of extracellular matrix (ECM) proteins. It is widely accepted that the activation of HSCs plays a critical role in liver fibrosis, which is characterized by excessive deposition of extracellular matrix components [4] . Similar cells in pancreas were isolated in the late 1990s [5] , and these pancreatic stellate cells (PSCs) also play an important role in pancreatic fibrogenesis in a manner analogous to HSCs [6] . Thus, stellate cells are considered as an attractive target for anti-fibrotic therapies [7] . Despite extensive investigations, there is, however, no effective therapy for liver fibrosis and end stage cirrhosis, except for the removal of the causative agent and organ transplantation.
Retinoids (vitamin A and its metabolites) regulate multiple physiological activities, such as vision, cell proliferation and differentiation [8] . Vitamin A, acquired from the diet, is transported to the liver and taken up by hepatocytes as a chylomicron remnant. It has been suggested that retinol binding protein (RBP) plays a role in the transfer of retinol from hepatocytes to HSCs via a RBP receptor STRA6 [9] . Upon HSC activation, some retinoid contents are oxidized to retinaldehyde, which is irreversibly further metabolized to retinoic 4 4 acid (RA) by retinaldehyde dehydrogenases (RALDH). This is supported by the fact that RA level is increased in activated stellate cells compared with pre-activated stellate cells, whereas the contents of retinyl ester and retinol decrease [10, 11] . In order to examine the role of RA in stellate cell activation, studies have undergone by assessing the effects of exogenous RA on HSCs or liver fibrosis, but the results are controversial; several studies showed that RA inactivated HSCs and alleviated hepatic fibrosis [12, 13] , while other reports showed the opposite [14, 15] . Studies showed that retinoids exert their biological effects primarily through binding to nuclear receptors, retinoic acid receptors (RAR) and retinoid X receptor (RXR) [16] .
Albumin is an abundant multifunctional plasma protein synthesized primarily by liver cells [17] . It, comprised of three homologous domains (I-III), binds a wide variety of hydrophobic ligands including fatty acids, retinoids [18, 19] . In a previous study, we showed that albumin was endogenously expressed in quiescent but not activated stellate cells and that its forced expression in activated stellate cells induced phenotypic conversion of myofibroblasts into fat-storing cell phenotype [20] . Based on this finding, we have developed the recombinant fusion protein R-III, in which albumin (domain III) is fused to the Cterminus of RBP [21] . RBP was adopted for stellate cell-targeting delivery because RBP and its membrane receptor STRA6 coordinate cellular uptake of retinol into HSCs [9, 22] . Our follow-up study showed that R-III inhibits HSC activation in vitro and reduces liver fibrosis in vivo [23, 24] . In this study, we examined the mode of action of albumin/R-III and found that RA sequestration by albumin/R-III downregulates TGF-/Samd3 signaling in HSCs.
Results
Retinoic acid is involved in the activation of hepatic stellate cells (HSCs) 5 5 Retinoic acid (RA) levels were reported to increase in activated HSCs [10] , and we previously showed that the inhibition of HSC activation by albumin expression and R-III treatment (albumin/R-III) was accompanied by a pronounced reduction of RA levels and its signaling [23] . In order to examine the role of RA in HSC activation, HSCs after passage 1 (HSCs-P1; activated HSCs) were treated with citral, a RALDH inhibitor that blocks RA biosynthesis, or AGN193109, a RAR antagonist, and analyzed by real-time PCR. Citral significantly downregulated the expression of -SMA and collagen type I, markers for activated stellate cells, whereas AGN193109 affected only -SMA expression ( Fig. 1A ).
This suggests that RA is involved in HSC activation through as yet unidentified pathway(s) rather than via its nuclear receptor RAR.
Next, we examined how the alterations in RA levels influence nuclear receptor signaling. Cell lysates were prepared from early-activated HSCs (HSCs at day 2 after plating;
HSCs-d2), HSCs-P1 and R-III-treated HSCs-P1, respectively, and immunoprecipitated using antibody against RXR, an obligatory heterodimerization partner. In parallel with RA levels reported, the heterodimer formation of RXR with RAR- was found to increase in activated HSCs compared with early-activated HSCs and decrease with R-III treatment ( Fig. 1B ). On the other hand, the heterodimer formation of RXR with PPAR-, a factor whose activity is decreased in activated HSCs and whose agonist suppresses several markers of HSC activation [25] , diminished in activated HSCs and remained undetectable even with R-III treatment.
This suggests that R-III partially reverses HSC activation.
RA sequestration is accompanied by nuclear translocation of NF-B in HSCs
The NF-B family of transcription factors are central players in inflammatory response, and they are normally sequestered in the cytosol by inhibitor B (IB) and upon 6 6 activation translocate to the nucleus [26] . As it was reported that RA exerts an antiinflammatory effect by inhibiting nuclear translocation of NF-B in microglial and neuronal cells [27, 28] , we assessed the subcellular localization of NF-B P65 in HSCs by immunofluorescence. P65 were found distributed evenly in the cytoplasm in activated HSCs, and, intriguingly, albumin/R-III led to a strong nuclear translocation of p65 ( Fig. 2 ). Such p65 nuclear translocation was not, however, detected in HSCs-P1 expressing mutant albumin (R410A, Y411A, K525A), in which three high affinity-fatty acid binding sites were substituted for alanine and whose expression failed to sequester RA [23] . This suggests that RA in activated HSCs may prevent nuclear import of NF-B p65. Indeed, RNA-seq analysis revealed that R-III treatment increased the expression of inflammation-related genes, such as IL-1, IL-1, IL-6 and TNF-, in HSCs-P1 (Table 1 ). Real-time PCR also confirmed that IL-1 expression was dramatically elevated by albumin/R-III by >100-fold (data not shown).
IL-1 mediates R-III effects on HSC activation
Previous reports showed that IL-1 neutralizes the activity of TGF-, a major driver of HSC activation, by different mechanisms, such as TGF- receptor type II (TGF-RII) downregulation, Smad7 upregulation, and Smad3 inhibition [29] [30] [31] . We first examined whether IL-1 influences HSC activation. Surprisingly, IL-1 expression in activated HSCs downregulated the mRNA expression of -SMA and collagen type I, as was seen with albumin expression and R-III treatment [20] (Fig. 3A ). We then tested whether R-III effects on -SMA and collagen type I is mediated by IL-1 and found that co-treatment with IL-1 receptor antagonist (IL-1RA) abolished R-III effects (Fig. 3B) . The time course of changes in mRNA levels of IL-1, -SMA and collagen I was examined with R-III treatment. R-III 7 7 induced a steady increase in IL-1 mRNA with a peak in expression at ~12 h (>100 fold) and simultaneously downregulated both -SMA and collagen I ( Fig. 3C ). Lastly, we investigated R-III effect on the mRNA levels of TGF-RII, smad7 and TGF-1, which are listed as TGF-/Smad3 target genes [32], and found modest but significant decreases in Smad7 and TGF- ( Fig. 3D ). Thus, these findings suggest that RA sequestration by albumin/R-III triggers nuclear import of NF-B and that the resulting IL-1 may mediate R-III effects on HSC activation.
Albumin/R-III inhibits nuclear translocation of smad3
As IL-1 was reported to affect subcellular distribution of Smad proteins [31], we tested whether increased production of IL-1 by albumin/R-III inhibits nuclear translocation of Smads. Immunofluorescence showed that both Smad2 and Smad3 were found accumulated in the nucleus in activated HSCs. Albumin/R-III was, however, found to block the nuclear import of smad3, but not Smad2, in a IL-1 dependent manner ( Fig. 4A and 4B ). As importin7 and 8 are reportedly responsible for transporting phosphorylated Smad2 and Smad3 into the nucleus [33] , we measured their expression levels but found no significant changes with R-III treatment ( Fig. 4C ).
IL-1 induces Smad3 linker phosphorylation
TGF--activated kinase 1 (TAK1) and its downstream targets, p38 and JNK, have been identified that phosphorylate Smad3 in the linker region and inhibit its nuclear translocation [34, 35] . Other studies also demonstrated that IL-1 inhibits TGF- signaling through Smad linker phosphorylation in a TAK1-dependent manner [31, 36] . We examined 8 8 whether albumin/R-III modulates the kinase activities and Smad3 linker phosphorylation via IL-1 in HSCs by western blot analysis. As it was reported that phosphorylation of TAK1 at Ser412 is required for activation of TAK1-mediated IL-1R signaling [37] , TAK1 S412 phosphorylation was increased by albumin/R-III ( Fig. 5A, Supplementary Fig. S1 ), but no significant change in phosphorylation at TAK1 autophosphorylation sites T184, T187 was observed. Importantly, albumin/R-III activated JNK, but not p38, and enhanced phosphorylation of Smad3 in the linker region (S208). Smad3 phosphorylation at the C terminus S423, S425 was not affected. These R-III effects on Smad3, JNK and -SMA were found to be dependent on IL-1 signaling (Fig. 5B ). In order to identify the kinase(s) responsible for Smad3 linker phosphorylation, we co-treated HSCs-P1 with R-III and the inhibitor for p38 (SB203580), JNK (SP600125) or TAK1 ((5Z)-7-Oxozeaenol) and found that Smad3 linker phosphorylation was reduced by (5Z)-7-Oxozeaenol and SP600125 ( Fig.   5C ). Real-time PCR also showed that the activity of TAK1 and JNK was required for R-III effects on -SMA and collagen type I, TGF-/Smad3 target genes ( Fig. 5D ). Lastly, in order to confirm the functional significance of Smad3 linker phosphorylation, we transfected HSCs-P1 with expression vector for wild-type or mutant Smad3 (S204A, S208A, S213A), in which three linker phosphorylation sites were substituted for alanine. R-III effects on the subcellular localization of Smad3 and on the expression of -SMA and collagen I were not detected in mutant Smad3-expressing HSCs ( Fig. 6A and 6B ). These findings suggest that IL-1 signaling induced by albumin/R-III inhibits nuclear import of Smad3 by linker phosphorylation.
Albumin mutation may be associated with hepatocellular carcinoma 9 9 As our finding suggests that RA sequestration by albumin/R-III downregulates not only RAR-mediated signaling but TGF-/Smad3 signaling, leading to the inhibition of HSC activation (Fig. 6C) , it is plausible to reason that mutations in the albumin gene, particularly at the sites that are involved in RA binding, may impair its anti-fibrotic activity in HSCs and predispose a person to fibrosis, cirrhosis and liver cancer, as cirrhosis is the major risk factor of hepatocellular carcinoma (HCC). Intriguingly, albumin gene was recently reported to be frequently mutated in liver cancer [38] . Among 82 locations of albumin gene mutations found in HCC, publicly available at www.cbioportal.org [39], 19 overlapped binding sites for RA and fatty acid [18, 19] and, more importantly, the most frequently mutated amino acid (K161) was found to be a RA binding site ( Fig. 6D ). RA binds also to the albumin fatty acid binding sites [40] . This high degree of overlap reinforces the anti-fibrotic role of albumin in HSCs.
Discussion
Hepatic stellate cells are considered an attractive target for anti-fibrotic therapies.
Several previous reports aimed to inactivate HSCs and reduce liver fibrosis, but no effective therapy for treating liver fibrosis is currently available [41] . Also the molecular mechanism for the activation of HSCs remains elusive despite intensive research efforts over the last 30 years.
Quiescent stellate cells store retinoids as retinyl esters in cytoplasmic lipid droplets.
Upon stellate cell activation, cytoplasmic lipid droplets collapse and a portion of the retinoid contents is likely released and metabolized to retinaldehyde and to retinoic acid (RA). The role of RA in HSC activation has been proposed, but previous reports about the effects of exogenous retinoids on HSCs and liver fibrosis were controversial [42] . On the other hand, we previously showed that endogenous RA may be involved in HSC activation [23] , and 10 10 demonstrated in this study that RA inhibits NF-B nuclear transport in HSCs (Fig. 2) .
Consistent with the previous finding that albumin expression and R-III treatment (albumin/R-III) sequestered cellular RA in HSCs [23, 24] , albumin/R-III allowed nuclear translocation of NF-B ( Fig. 2 ) and led to a dramatic increase in IL-1 expression. IL-1 signaling in turn activated TAK1 and its downstream molecule JNK (Fig. 5A) , phosphorylated Smad3 in the linker region, inhibiting nuclear transport of Smad3 (Fig. 4A) . As a result, albumin/R-III in HSCs downregulated the expression of Smad3-target genes, such -SMA, collagen type I, TGF-RII, Smad7, and TGF-. This mode of action for albumin/R-III was further supported by the finding that mutation of the Smad3 linker phosphorylation sites (S204A, S208A, S213A) abolished R-III effects on Smad3 (Fig. 6A) . Thus, the anti-fibrotic effects of albumin and R-III is probably due to reduction in cellular RA levels. This explains the reason why mutant albumin (R410A/Y411A/K525A), in which three of five high affinity fatty acidbinding sites were substituted for alanine and whose expression failed to sequester RA, did not inhibit HSC activation [20, 23] .
Previous studies demonstrated that inflammatory mediators play a role in HSC activation [43] , but we showed in this study a direct inhibitory interaction between the IL-1 and TGF- signaling in HSCs. As albumin is expressed only in pre-activated HSCs and inhibits HSC activation, it may be used as a reliable marker for pre-activated HSCs.
Retinoid-storing stellate cells also exist in extrahepatic organs such as pancreas, kidney, spleen, intestine and lung [44] . These cells show striking similarities in morphology and perivascular location, which suggests that activated stellate cells may contribute to the myofibroblast cells seen in the fibrotic extrahepatic tissues [6] . As intravenously injected R-III was detected also in extrahepatic organs such as lung, pancreas, kidney and intestine [21], we are investigating whether R-III reduces extrahepatic fibrosis. In the present study, we 11 11 elucidated the mode of action of albumin/R-III, and this study suggests that R-III, designed for stellate cell-targeting, may be a novel anti-fibrotic drug candidate.
Materials and methods

Materials
Male BALB/c mice (9 weeks of age) were purchased from Central Lab Animal, Inc. (Seoul, Korea) and maintained in proper condition. Animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) in Korea University. Mouse R-III fusion protein was prepared as previously described [23] . Citral, IL-1 receptor antagonist, (5Z)-7-Oxozeaenol, SB203580 and SP600125 were purchased from Sigma-Aldrich (St. Louis, MO, USA) and AGN193109 purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Isolation of Mouse hepatic stellate cells (HSCs)
Mouse HSCs were isolated from wild-type male BALB/c mice (14 weeks old) as previous described [45] with some modifications. Briefly, liver was in situ perfused with phosphatebuffered saline (PBS) and then Gey's balanced salt solution (GBSS) supplemented with collagenase, pronase (Sigma-Aldrich, St. Louis, MO, USA) and DNase (MP Biomedicals, Santa Ana, CA, USA). The perfused liver was dissected and the gall bladder and connective tissue attached to the liver were removed. The liver cell suspensions were further digested for 12 min in a 37C water bath in GBSS supplemented with collagenase, pronase and DNase.
The cells were then washed and centrifuged in a 13.4% Nycodenz gradient at 1400 g for 20 min without brake. The interface containing enriched HSC was taken, washed by GBSS, and HSCs were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The purity of stellate cells was assessed by microscopic observation and western blotting using anti-tyrosine aminotransferase antibody. The isolated 12 12 cells were permitted to activate 4 days in culture and were then trypsinized and plated. Activation status of HSCs was assessed by increased expression of -SMA and morphological changes.
Quantitative Real-Time PCR
Total RNA was prepared using TRIzol (Ambion, Austin, TX, USA) and cDNA synthesized from total RNA. Quantitative real-time PCR was performed using an ABI QuantStudio TM 3
Real-Time PCR System. To control for variations in the reactions, PCR products were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The primers used were listed in Table S1 .
Western blot analysis
Cell lysates were prepared, and electrophoresis and immunoblotting were performed as described [23] . 
Immunofluorescence
HSCs were plated onto glass coverslips coated with gelatin. Samples were fixed in 4% paraformaldehyde, permeabilized, blocked, and incubated with antibodies against p65 (Cell Signaling Technology #8242), Smad2 and Smad3 (Cell Signaling Technology #5339, #9523) overnight at 4°C in a moist chamber, followed by Alexa Fluor® 594-conjugated secondary antibody. Cells then were stained with DAPI, washed with PBS and mounted onto slides.
Stained cells were visualised on a Leica DM6000 B fluorescence microscope (Leica Microsystem, Buffalo Grove, IL).
RNA-seq
Detailed experimental procedure for RNA preparation and RNA-seq is provided in Supplementary information. 14 14 Results are expressed as mean ± standard deviation (SD). Paired statistical analysis was done using t tests. Comparisons were considered significant at p,0.05 and p values were two tailed. HSCs-P1 were treated with HPLC-purified R-III (0.3µM) or transfected with plasmid encoding wild-type or mutant albumin (R410A/Y411A/K525A), and analyzed by immunofluorescence using anti-p65 antibody. The cell nuclei were stained with DAPI (blue). 
Statistical analysis
Figure legends
Table 1
Total RNA was extracted from HSCs at day 2, 5 after plating (HSCs-d2, HSCs-d5) and from HSCs after passage 1 (HSCs-P1) and R-III-treated HSCs-P1, and analyzed by RNA sequencing. 8 8 FIG. S1. HSCs-P1 were transfected with albumin expression vector and cell lysates were analyzed by western blotting. The Western blots are representative of three independent experiments from separate cell preparations. α-tubulin was used as a loading control.
Supplementary Information
Materials and Methods
mRNA-Seq Data
In order to construct cDNA libraries with the TruSeq Stranded mRNA LT Sample Prep Kit, total RNA was extracted from HSCs. The protocol consisted of polyA-selected RNA extraction, RNA fragmentation, random hexamer primed reverse transcription and 100nt paired-end sequencing by Illumina NovaSeq 6000. The libraries were quantified using qPCR according to the qPCR Quantification Protocol Guide and qualified using an Agilent Technologies 2100 Bioanalyzer. We preprocessed the raw reads from the sequencer to remove low quality and adapter sequence before analysis and aligned the processed reads to the Mus musculus (mm10) using HISAT v2.1.0 (1). HISAT utilizes two types of indexes for alignment (a global, whole-genome index and tens of thousands of small local indexes). These two types' indexes are constructed using the same BWT (Burrows-Wheeler transform)/ a graph FM index (GFM) as Bowtie2. Because of its use of these efficient data structures and algorithms, HISAT generates spliced alignments several times faster than Bowtie and BWA widely used. The reference genome sequence of Mus musculus (mm10) and annotation data were downloaded from the NCBI. And then, transcript assembly of known transcripts, novel transcripts, and alternative splicing transcripts was processed by StringTie v1.3.4d (2, 3) . Base on the result of that, expression abundance of transcript and gene were calculated as read count or FPKM value (Fragments Per Kilobase of exon per Million fragments mapped) per sample. The expression profiles are used to do additional analysis such as DEG (Differentially Expressed Genes). In groups with different conditions, differentially expressed genes or transcripts can be filtered through statistical hypothesis testing.
For variant calling of RNA-Seq data, trimmed reads were aligned to Mus musculus
